The use of sugammadex to reverse rocuronium‐induced anaphylaxis in the intensive care unit. Issue 2 (24th July 2017)

• Record Type: Journal Article
• Authors: Leggatt, Ricki; Elkady, Hatem
• Is Part Of: Anaesthesia cases. Volume 5:Issue 2(2017)
• Page Start: 8
• Page End: 11
• Publication Date: 2017-07-24
• Subjects: 617.9605
• DOI: 10.21466/ac.TUOSTRR.2017
• Languages: English
• ISSNs: 2396-8397

Abstract

Summary: Rocuronium is increasingly used as the neuromuscular blocking agent of choice in the ICU due to a favourable side effect profile compared with suxamethonium. However, it potentially causes anaphylaxis with one in every 2499 patient exposures. Reports in anaesthetic literature describe the use of sugammadex as a novel treatment for rocuronium‐induced anaphylaxis, but it is not recommended for routine use. No literature specifically relating to ICU patients exists. We describe a case of severe rocuronium‐induced anaphylaxis on ICU, resistant to conventional therapy and resulting in cardiac arrest, being completely reversed by 200 mg sugammadex.